PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
H. pluvialis attenuated renal fibrosis by restoring mitophagy and reversing epithelial-mesenchymal transition (EMT) in rat models and HK-2 cells [PMID:41381553]
Suggested benefits include anti-inflammation, immunomodulation, LDL cholesterol oxidation suppression, improved semen quality, and attenuation of eye fatigue [PMID:33783748]
Potential pharmacological effects include anti-diabetic, anti-inflammatory, and protective properties for the cardiovascular, ocular, and skin systems [PMID:34770879, PMID:32906619]
Evidence summary
PubMed sources
- 1.PMID: 34424829 (2022) — Astaxanthin from Haematococcus pluvialis: processes, applications, and market. · Preparative biochemistry & biotechnology
- 2.PMID: 34770879 (2021) — Haematococcus pluvialis as a Potential Source of Astaxanthin with Diverse Applications in Industrial Sectors: Current Research and Future Directions. · Molecules (Basel, Switzerland)
- 3.PMID: 32906619 (2020) — Astaxanthin and other Nutrients from Haematococcus pluvialis-Multifunctional Applications. · Marine drugs
- 4.PMID: 39059842 (2024) — Advances in microbial astaxanthin production. · Advances in applied microbiology
- 5.PMID: 34653624 (2022) — Cell disruption and astaxanthin extraction from Haematococcus pluvialis: Recent advances.